Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Royalty Pharma (NASDAQ:RPRX – Get Rating) had its price objective raised by Morgan Stanley from $48.00 to $50.00 in a report published on Monday, The Fly reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts have also recently issued reports about the stock. Tigress Financial raised their price […]
Royalty Pharma (NASDAQ:RPRX – Get Rating) had its target price lifted by investment analysts at Morgan Stanley from $48.00 to $50.00 in a note issued to investors on Monday, The Fly reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 36.87% from […]
Graypoint LLC lessened its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 47.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,975 shares of the biopharmaceutical company’s stock after selling 40,026 shares during the period. Graypoint LLC’s holdings in Royalty Pharma were […]
Versor Investments LP boosted its position in Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 69.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 32,790 shares of the biopharmaceutical company’s stock after purchasing an additional 13,490 shares during the quarter. Versor Investments LP’s holdings in Royalty Pharma were worth $1,296,000 at the end […]